EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against AcelRx Pharmaceuticals, Inc. – ACRX

Loading...
Loading...
NEW YORK--(BUSINESS WIRE)--

The Rosen Law Firm, P.A., a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of AcelRx Pharmaceuticals, Inc. ACRX resulting from allegations that AcelRx may have issued materially misleading business information to the investing public.

On March 9, 2015, the Company announced that last week it had received correspondence from the Food and Drug Administration ("FDA") stating that in addition to the bench testing and two Human Factors studies that have already been performed, an additional clinical study is needed to assess the risk of inadvertent dispensing and overall risk of dispensing failures. On this news, shares of AcelRx fell over 1/3 during intraday trading on March 9, 2015.

The Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by AcelRx investors. If you purchased shares of AcelRx before March 9, 2015, please visit the website at http://rosenlegal.com/cases-538.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

The Rosen Law Firm, P.A.
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
kchan@rosenlegal.com
www.rosenlegal.com

Loading...
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...